Table 2.
Adjusted hazard ratios and 95%CI for death, either with complete available time-at-risk or with follow-up ended 5 years after colorectal cancer diagnosis
| n | Deaths | aHR1 (95%CI) | n | Deaths | aHR2 (95%CI) | n | Deaths | aHR13 (95%CI) | |
| Complete follow-up | |||||||||
| No IBD | 6952 | 2013 | Ref. | 6567 | 1926 | Ref. | 3836 | 1322 | Ref. |
| IBD | 250 | 74 | 1.08 (0.85-1.36) | 242 | 71 | 1.09 (0.85-1.40) | 81 | 26 | 1.20 (0.81-1.79) |
| P value | 0.54 | 0.48 | 0.36 | ||||||
| 5-yr follow-up | |||||||||
| No IBD | 6903 | 1372 | Ref. | 6526 | 1320 | Ref. | 3801 | 871 | Ref. |
| IBD | 249 | 63 | 1.36 (1.05-1.76) | 241 | 60 | 1.34 (1.02-1.77) | 81 | 24 | 1.52 (1.00-2.30) |
| P value | 0.018 | 0.037 | 0.048 |
1
Adjusted for age, recruitment phase, sex, and endoscopy;
2
Additional adjustment for surveillance epidemiology and end results summary stage (local, regional, distant);
3
Inflammatory bowel disease (IBD) confirmed from medical and pathology records at Seattle and Ontario centers only, non-IBD associated cases restricted to these centers. aHR: Adjusted hazard ratio.